Rapid and reliable autologous cell screening and expansion for organoid therapy
Active Other Transaction Agreement Awarded Last action
- Contract number
- 140D042690016
- Awardee
-
Acrocyte Therapeutics Inc. UEI WAKUBM87P2A4
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $2,653,048
Award facts
- Contract value 61% obligated
-
- $2,653,048.00 Current, with exercised options
- $4,371,496.00 Potential, with all options
- Completion date 20% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institutes of Health Department of Health and Human Services
- NAICS code
- Not on record
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Fremont, CA 94538, USA
Award details come from SAM.gov/FPDS.
About this award
Acrocyte Therapeutics Inc. has been awarded an Other Transaction Agreement valued at $4.37M by the National Institutes of Health (NIH) to develop rapid and reliable autologous cell screening and expansion technologies for organoid therapy. The contract, awarded on March 19, 2026, with an ultimate completion date of March 18, 2029, will be performed at the company's facility in Fremont, California. This effort supports NIH's broader mission to advance regenerative medicine and cell-based therapeutic approaches by enabling efficient processing and quality assessment of patient-derived cells for therapeutic applications.
The use of an Other Transaction Agreement vehicle reflects the innovative nature of this work and NIH's commitment to supporting cutting-edge biotechnology development outside traditional contracting mechanisms. Autologous cell-based organoid therapies represent a promising frontier in personalized medicine, and this project will likely enhance the scalability and reliability of manufacturing processes critical for translating such therapies from research to clinical implementation. The three-year performance period positions the contractor to achieve substantial technical milestones in cell screening methodologies and expansion protocols that could advance the field of regenerative medicine.
Quick answers
Who was awarded contract 140D042690016?
140D042690016 was awarded to Acrocyte Therapeutics Inc. by Interior Business Center (Office of Policy Management and Budget) on March 19, 2026.
How much is contract 140D042690016 worth?
The government has obligated $2,653,048 on 140D042690016. Its potential value, with all options, is $4,371,496.
Which agency awarded contract 140D042690016?
Interior Business Center (Office of Policy Management and Budget) awarded 140D042690016, with funding from National Institutes of Health (Department of Health and Human Services).
Was contract 140D042690016 competed?
The extent of competition for 140D042690016 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award